Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O75449
UPID:
KTNA1_HUMAN
Alternative names:
p60 katanin
Alternative UPACC:
O75449; E1P5A3; Q5TFA8; Q5TFA9; Q86VN2; Q9NU52
Background:
Katanin p60 ATPase-containing subunit A1, also known as p60 katanin, plays a pivotal role in cellular dynamics by severing microtubules in an ATP-dependent manner. This action facilitates the rapid reorganization of microtubule arrays and is crucial for processes such as mitotic spindle disassembly and axonal growth, by enabling microtubule release and transport within neurons.
Therapeutic significance:
Understanding the role of Katanin p60 ATPase-containing subunit A1 could open doors to potential therapeutic strategies.